Case Report

Spontaneous bone infarction of the distal femur in a patient with Cushing’s disease: a case report

Pepijn van Houten a, Jacky de Rooy b, Ingrid van der Geest c, Romana Netea-Maier a, Annenienke van de Ven a,*, Wouter Wijnhoven a,*, Jacky de Rooy a,†, Ingrid van der Geest a,†, Jacky de Rooy a

a Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre, Nijmegen, the Netherlands
b Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands
c Department of Orthopedic Oncologic Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands

A R T I C L E  I N F O

Keywords:
Cushing’s disease
Bone infarction
Avascular necrosis
Osteonecrosis

A B S T R A C T

Avascular necrosis of the femoral head is a well-known complication of treatment with high dosage glucocorticoids and has been described in a few patients with Cushing’s syndrome. In this case report, we describe the, to our knowledge, first case of a patient with endogenous Cushing’s syndrome with a bone infarction located in the distal femur. In patients with Cushing’s syndrome and bone pain, the diagnosis of bone infarction should be considered as it can occur as a rare complication of hypercortisolism.

1. Introduction

The use of glucocorticoids is associated with the development of bone infarction, also known as osteonecrosis or avascular necrosis (AVN). Avascular necrosis of the femoral head, which is one of the most commonly affected localizations, is a well-known complication of treatment with high dosage glucocorticoids and has been described in a few patients with endogenous Cushing’s syndrome (Belmahi et al., 2018; Bukhman et al., 1987; Camporro et al., 2016; Cerletty et al., 1973; Güven et al., 2009; Ko et al., 2004; Kobayashi and Terayama, 1991; Koch et al., 1999; Modrono et al., 2014; Pâdurescu et al., 2016; Phillips et al., 1986; Premkumar et al., 2013; Sharon et al., 1977; Takada et al., 2004; Wicks et al., 1987). Here, we present a case of a 22-year old male patient with severe hypercortisolism due to Cushing’s disease, who developed a spontaneous bone infarction of the distal femur.

2. Case description

A 22-year old male patient with no previous medical history was referred to our tertiary center with suspicion of Cushing’s syndrome. During the last two years, he suffered from complaints of fatigue, gain of weight (10 kg) and psychological problems. Physical examination showed a cushingoid appearance with full moon face, supraclavicular fat pads, abdominal obesity, proximal muscle wasting, reddish-purple striae at the abdomen and upper arms, cutaneous fungal infection and hematomas. Biochemical analysis confirmed ACTH dependent severe hypercortisolism: cortisol concentration after 1 mg dexamethasone suppression test (DST) was 0.61 μmol/l (normal value (n) < 0.05 μmol/l), 24-h urine free cortisol level was 2260 nmol (n < 150 nmol), late night salivary cortisol concentration was 39.0 nmol/l (n < 3.0 nmol/l) and adrenocorticotropic hormone (ACTH) concentration was 28.8 pmol/l (n 1.6–13.9 pmol/l) (Nieman et al., 2008). Pituitary MRI showed a lesion of 8 × 5 mm in the anterior pituitary gland and the patient was referred to the neurosurgeon for resection of the adenoma. Endoscopic endonasal transsphenoidal surgery was performed followed by remission of Cushing’s syndrome. Pathological examination of the resected tissue showed an ACTH-producing adenoma.

For 5 months prior to the diagnosis of Cushing’s disease, the patient suffered from pain in his left upper leg, for which he was referred to the orthopedic surgeon. Physical examination showed normal knee function without swelling or pain. There was no axial pressure pain in the upper leg.

Conventional X-ray of the distal femur showed a probable sheath-like intramedullary lucency, which was only recognized in retrospect after

Abbreviations: CS, Cushing’s syndrome; AVN, avascular necrosis; DST, 1 mg dexamethasone suppression test; n, normal value; ACTH, adrenocorticotropic hormone; MRI, magnetic resonance imaging; ALL, acute lymphoblastic leukemia; LMWH, low-molecular weight heparin.

* Corresponding author at: Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre, PO box 9101, 6500 HB Nijmegen, the Netherlands.

E-mail address: annenienke.vandeven@radboudumc.nl (A. van de Ven).

https://doi.org/10.1016/j.bonr.2021.100756
Received 3 January 2021; Received in revised form 13 February 2021; Accepted 13 February 2021
Available online 18 February 2021
2352-1872/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Bone infarctions are commonly reported events during treatment with high dosage glucocorticoids with a prevalence between 3% and 38%, depending on the underlying disease and the used dosage of glucocorticoids (Assouline-Dayan et al., 2002). For example, high incidences of bone infarctions are found in pediatric patients treated for acute lymphoblastic leukemia (ALL) and in pediatric patients who have undergone allogenic bone marrow transplantation (Kaste et al., 2011). Both of these groups receive high dosages of glucocorticoids. In addition, a cohort study in patients with different kinds of chronic inflammatory diseases showed an association between glucocorticoid exposure and avascular necrosis, especially in young adults (Horton et al., 2017). Other risk factors include: alcohol abuse, hematological diseases such as sickle cell anemia or thalassemia, hypercholesterolemia, chronic renal failure, autoimmune diseases, pregnancy and hyperparathyroidism (Chan and Mok, 2012; Moskal et al., 1997; Poignard et al., 2012; Wang et al., 2003). The knee is the second most common affected localization of bone infarctions, although much less common than the hip (Chan and Mok, 2012; Mont et al., 2000). Other localizations of bone infarctions are the shoulder and ankle. The specific prevalence of bone infarctions of the distal femur is not known.

The pathogenesis of glucocorticoid induced bone infarctions is not fully understood. Hypotheses include fat cell hypertrophy, fat embolization, intravascular coagulation and osteocyte apoptosis (Chan and Mok, 2012). Fat cell hypertrophy might increase intramedullary pressure and reduce venous return, which are hypothesized to lead to bone infarctions as well (Motomura et al., 2005). One animal study has shown that treatment with the low-molecular-weight heparin (LMWH) enoxaparin (Clexane) has the potential to prevent steroid-induced bone infarctions (Beckmann et al., 2014). In the mentioned study, the bone infarctions were induced by systemic treatment with methylprednisolone. This might indicate that intravascular coagulation plays an important role in the pathogenesis of bone infarctions. Furthermore, because of down-regulation of vascular endothelial growth factor, glucocorticoids can induce hypoperfusion of the bone, which might result in bone infarction (Wang et al., 2010). Lastly, it is known that hypercortisolism can lead to endothelial dysfunction (Wagenmakers et al., 2016). Glucocorticoids increase vascular smooth muscle contractility and decrease endothelial-dependent vasodilatation (Walker, 2007). One could hypothesize that this altered vascular tone might lead to decreased blood flow in tissues and thus may contribute to the pathogenesis of glucocorticoid induced bone infarctions.

The golden standard for diagnosing bone infarctions is MRI, while conventional X-ray is less sensitive (Kaste et al., 2011). Bone infarctions can be managed conservatively or surgically. Indication for one or the other depends on stage of disease, size of the lesion, age and comorbidities of the patient (Chan and Mok, 2012). If pain relief is required, core decompression can be performed. During this procedure intramedullary pressure is reduced by making a drill hole, which improves blood flow (Chan and Mok, 2012). To strengthen the bone near the joint, bone impaction grafting can be performed (Rijnen et al., 2006). If the joint has been destroyed by the bone infarction, joint replacement is necessary (Chan and Mok, 2012). Furthermore, bisphosphonates may reduce pain and improve functionality (Luo et al., 2014).

4. Conclusion

In conclusion, the patient presented is to our knowledge the first described case of bone infarction of the distal femur in a patient with severe endogenous Cushing’s syndrome. In patients with Cushing’s syndrome and bone pain, the diagnosis of bone infarction should be considered as it can occur as a rare complication of hypercortisolism.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Pepijn van Houten: Writing - original draft; Writing – review & editing; Jacky de Rooy: Writing - original draft; Visualization; Ingrid van
Fig. 2. T2 weighted axial (left) and proton density weighted sagittal (right) MR images of the left distal femur with fat saturation. Serpigenous intramedullary high signal lines (arrows) surrounding normal fatty marrow (asterix) in the distal femoral diaphysis.

der Geest: Writing - original draft; Romana Netea-Maier: Writing - review & editing; Annenienke van de Ven: Conceptualization; Supervision; Writing – review & editing.

Declaration of competing interest

All authors declare no competing interests.

References

Assouline-Dayan, Y., et al., 2002. Pathogenesis and natural history of osteonecrosis. In: Seminars in Arthritis and Rheumatism. Elsevier.

Beckmann, R., et al., 2014. Enoxaparin prevents steroid-related avascular necrosis of the femoral head. Sci. World J. 2014.

Belmahi, N., et al., 2018. Avascular necrosis of the femoral head: an exceptional complication of cushing’s disease. Annals of African Medicine 17 (4), 225–227.

Bukhman, A., et al., 1987. Aseptic femur head necrosis in endogenous hypercorticism. Revue de chirurgie orthopedique et reparatrice de l’appareil moteur 77 (5), 362.

Chan, K., Mok, C., 2012. Glucocorticoid-induced avascular bone necrosis: diagnosis and management. The Open Orthopaedics Journal 6, 449.

Cerletty, J.M., Ziebert, A.P., Mueller, K.H., 1973. Avascular necrosis of the femoral head = Appareil moteur 77 (5), 362.

Cohen, P., et al., 1999. Cushing’s disease presenting with avascular necrosis of the hip: an orthopedic emergency. The Journal of Clinical Endocrinology & Metabolism 84 (9), 3010–3012.

Lindholm, J., et al., 2001. Incidence and late prognosis of Cushing’s syndrome: a population-based study. The Journal of Clinical Endocrinology & Metabolism 86 (1), 117–123.

Luo, R.-B., et al., 2014. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 20, 2439.

Modrzejewski, N., et al., 2018. Avascular necrosis of the femoral head: an exceptional syndrome is comparable with that in BMI-matched controls. The Journal of Clinical Endocrinology & Metabolism 93 (5), 1526–1540.

Mont, M.A., et al., 2000. Atraumatic osteonecrosis of the knee. JBJS 82 (9), 1279.

Mok, L., Yopping, R., Franklin, L., 1997. Hypercholesterolemia: an association with osteonecrosis of the femoral head. American Journal of Orthopedics (Belle Mead, NJ) 26 (9), 609–612.

Motomura, G., et al., 2005. Bone marrow fat-cell enlargement in early steroid-induced osteonecrosis—a histomorphometric study of autopsy cases. Pathology-Research and Practice 200 (11–12), 807–811.

Niemann, L.K., et al., 2008. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 93 (5), 1526–1540.

Pazderska, A., et al., 2016. Spontaneous resolution of avascular necrosis of femoral heads following cure of Cushing’s syndrome. Endocrinology, Diabetes & Metabolism Case Reports 2016 (1).

Phillips, K., et al., 1986. Avascular necrosis of bone: a manifestation of Cushing’s disease. South. Med. J. 79 (7), 825–829.

Poignard, A., et al., 2012. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. JBJS 94 (2), 156–162.

Premkumar, M., et al., 2013. Avascular osteonecrosis of femoral head in a post-operative patient of pituitary Cushing’s disease. J. Assoc. Physicians India 61, 413–415.

Rijken, W.H., et al., 2006. Bone impaction grafting for corticosteroid-associated osteonecrosis of the knee. JBJS 88 (suppl_3), 62–68.

Sharon, P., et al., 1977. Aseptic necrosis of head of femur: presenting manifestation in Cushing’s disease. J. Rheumatol. 4 (1), 73–75.

Takada, J., et al., 2004. Rapidly destructive coxarthropathy with osteonecrosis and osteoporosis caused by Cushing’s syndrome. Orthopedics 27 (10), 1111–1113.

Wagenmakers, M., et al., 2016. Vascular health in patients in remission of Cushing’s syndrome is comparable with that in BMI-matched controls. The Journal of Clinical Endocrinology & Metabolism 101 (11), 4142–4150.

Wallace, B.R., 2007. Glucocorticoids and cardiovascular disease. Eur. J. Endocrinol. 157 (5), 545–555.

Wang, Y., et al., 2003. Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clinical Orthopaedics and Related Research® 410, 213–224.

Wang, G., et al., 2010. Changes in femoral head blood supply and vascular endothelial growth factor in rabbits with steroid-induced osteonecrosis. J. Int. Med. Res. 38 (3), 1060–1069.

Wicks, I., et al., 1987. Cushing’s disease presenting with avascular necrosis of the femoral heads and complicated by pituitary apoplexy. Ann. Rheum. Dis. 46 (10), 783–786.